The Role of LncRNA CASC2 on Prognosis of Malignant Tumors: a Meta-analysis and Bioinformatics

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Aug 14

PMID 30100741

Citations 6

Authors

Lingling Yu

Shengsong Chen

Hui Bao

Weifang Zhang

Minqi Liao

Qian Liang

Xiaoshu Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Cancer susceptibility candidate 2 (CASC2) is characterized as a tumor suppressor, which was first identified to be downregulated in endometrial carcinoma. Accumulating evidence was provided to testify the function of CASC2 in malignant tumors. However, a systematic and quantitative assessment is not available. The present study was designed to evaluate the role of CASC2 in multiple carcinomas through meta-analysis and bioinformatics.

Materials And Methods: A systematic assessment of the relationship of CASC2 with tumors was performed by using several computerized databases from inception to December 1, 2017. Pooled HR with 95% CI was calculated to summarize the effect. The data on prognosis of malignant tumors were also downloaded from The Cancer Genome Atlas (TCGA) project, OncoLnc, TANRIC and lncRNAtor database.

Results: A total of 13 studies with 966 cancer patients were pooled in the analysis to evaluate the prognostic value of CASC2 in multiple tumors and the clinical features. The results of the meta-analysis revealed that low expression levels of CASC2 were associated with poor overall survival (OS) (pooled HR=0.39, 95% CI: 0.28-0.53, <0.0001). CASC2 obviously has a negative correlation with advanced tumor node metastasis (TNM) stage, lymph node metastasis (LNM) and T stage, respectively (<0.05). There was, however, no significant difference in gender, distant metastasis and high differentiation (>0.05). In the Kaplan-Meier curves with log-rank analysis, higher expression of CASC2 was positively correlated with longer survival time than patients with a lower level (<0.05), including kidney renal clear cell carcinoma, brain lower grade glioma, pancreatic adenocarcinoma and sarcoma.

Conclusion: Findings from this meta-analysis suggest that lower expression of CASC2 is associated with poorer prognosis of cancers, as well as advanced TNM, LNM and T stage. Data from the bioinformatics analysis revealed that higher expression of CASC2 was related to longer OS in patients with malignant tumors.

Citing Articles

Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma.

Zuo D, Chen Y, Zhang X, Wang Z, Jiang W, Tang F Cancer Biol Med. 2021; .

PMID: 34403221 PMC: 9334760. DOI: 10.20892/j.issn.2095-3941.2020.0516.

Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target in lung adenocarcinoma.

Chen S, Lu Z, Chen X, Wu X, Tu H, Yu L Oncol Lett. 2020; 20(5):147.

PMID: 32934715 PMC: 7471708. DOI: 10.3892/ol.2020.12010.

Long non‑coding RNA CASC2 suppresses pancreatic cancer cell growth and progression by regulating the miR‑24/MUC6 axis.

Xu D, Wang L, Zhou J Int J Oncol. 2020; 56(2):494-507.

PMID: 31894271 PMC: 6959463. DOI: 10.3892/ijo.2019.4937.

The expression and prognostic significance of Drp1 in lung cancer: A bioinformatics analysis and immunohistochemistry.

Yu L, Xiao Z, Tu H, Tong B, Chen S Medicine (Baltimore). 2019; 98(48):e18228.

PMID: 31770286 PMC: 6890372. DOI: 10.1097/MD.0000000000018228.

Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis.

Ye J, Sun H, Feng Z, Zhang Q, Xia Y, Ji Y Biosci Rep. 2019; 39(10).

PMID: 31227613 PMC: 6822487. DOI: 10.1042/BSR20190608.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Li L, Zhang L, Zhang Y, Zhou F . Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. Biomed Pharmacother. 2015; 72:109-12. DOI: 10.1016/j.biopha.2015.04.007. View

Cao Y, Xu R, Xu X, Zhou Y, Cui L, He X . Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 2016; 14(1):1019-25. DOI: 10.3892/mmr.2016.5337. View

Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D . BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014; 8(2):869-875. PMC: 4081361. DOI: 10.3892/ol.2014.2154. View

Geisler S, Coller J . RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14(11):699-712. PMC: 4852478. DOI: 10.1038/nrm3679. View

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C . Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 2017; 16(1):123. PMC: 5514467. DOI: 10.1186/s12943-017-0702-z. View

Zhou J, Huang H, Tong S, Huo R . Overexpression of long non-coding RNA cancer susceptibility 2 inhibits cell invasion and angiogenesis in gastric cancer. Mol Med Rep. 2017; 16(4):5235-5240. PMC: 5647078. DOI: 10.3892/mmr.2017.7233. View

10.

Zhou S, Wang J, Zhang Z . An emerging understanding of long noncoding RNAs in kidney cancer. J Cancer Res Clin Oncol. 2014; 140(12):1989-95. DOI: 10.1007/s00432-014-1699-y. View

11.

Takahashi K, Yan I, Haga H, Patel T . Long noncoding RNA in liver diseases. Hepatology. 2014; 60(2):744-53. PMC: 4110118. DOI: 10.1002/hep.27043. View

12.

Loewer S, Cabili M, Guttman M, Loh Y, Thomas K, Park I . Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010; 42(12):1113-7. PMC: 3040650. DOI: 10.1038/ng.710. View

13.

Gan Y, Han N, He X, Yu J, Zhang M, Zhou Y . Long non-coding RNA CASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma. Tumour Biol. 2017; 39(6):1010428317706229. DOI: 10.1177/1010428317706229. View

14.

Yu Y, Liang S, Zhou Y, Li S, Li Y, Liao W . HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling. J Cell Biochem. 2017; 120(3):2816-2827. DOI: 10.1002/jcb.26395. View

15.

Djebali S, Davis C, Merkel A, Dobin A, Lassmann T, Mortazavi A . Landscape of transcription in human cells. Nature. 2012; 489(7414):101-8. PMC: 3684276. DOI: 10.1038/nature11233. View

16.

Kumar A, Purohit R . Use of long term molecular dynamics simulation in predicting cancer associated SNPs. PLoS Comput Biol. 2014; 10(4):e1003318. PMC: 3983272. DOI: 10.1371/journal.pcbi.1003318. View

17.

Yang X, Xie X, Xiao Y, Xie R, Hu C, Tang B . The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 2015; 360(2):119-24. DOI: 10.1016/j.canlet.2015.02.035. View

18.

Wang P, Liu Y, Yao Y, Li Z, Li Z, Ma J . Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell Signal. 2014; 27(2):275-82. DOI: 10.1016/j.cellsig.2014.11.011. View

19.

Huang G, Wu X, Li S, Xu X, Zhu H, Chen X . The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer. Sci Rep. 2016; 6:26524. PMC: 4873821. DOI: 10.1038/srep26524. View

20.

Khachane A, Harrison P . Mining mammalian transcript data for functional long non-coding RNAs. PLoS One. 2010; 5(4):e10316. PMC: 2859052. DOI: 10.1371/journal.pone.0010316. View